Audit: QRS - Centrophenoxine for Health & Longevity
Audit conducted on 29/06/2026 05:34 using AI4L / Opus 4.8
Summary
| Items | Count |
|---|---|
| Total | 91 |
| Passed | 86 |
| Failed | 0 |
| N/A | 5 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | All QRS content traces to the ER (at-a-glance to Conclusion, protocol to Therapeutic Protocol, benefits/risks/monitoring to their sections). |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Speculative risk “Theoretical concern from the pCPA moiety…” mirrors ER line 229–231; “long-term safety unknown” matches ER. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | “Pregnancy or breastfeeding” listed as a contraindication, matching ER “Populations who should avoid it” (line 264). |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications/interactions sourced from the ER’s interactions section; benefits/risks from their respective sections; no cross-category relabeling. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | The QRS carries no PMIDs, NCT IDs, expert names, or brand names. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions introduced. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Sober, evidence-cautious tone matches the ER. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Maintained throughout. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Presents information without prescribing. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Footer disclaimer present; body presents evidence. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No advisory verbs in the QRS voice. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person address. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms minimized; “age pigment” used in plain quotes. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Compact cells and lists. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | No direct address. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Framing fits this audience. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Protocol/monitoring detail assumes a willing audience. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Not general-population framing. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Longevity/cognitive-resilience framing preserved. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging”. Proper names that contain “anti-aging” are quoted verbatim. | 🟢 | “Health & Longevity” used; no “anti-aging” in the QRS voice. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language. Direct quotes from sources are exempt. | 🟢 | “Memory drug” and “age pigment” are accessible but accurate plain-language renderings consistent with the at-a-glance plain-language requirement; no consumer-grade slang. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card/section headings (“Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”); Gate headings (“Contraindications”, “Key Interactions”); Tier labels (“High”, “Medium”, “Low”, “Speculative”); Table column headers in Monitoring (“Marker”, “Target”, “Why”). | 🟢 | All fixed headings and labels present and unmodified. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | Full standard span set present (45 spans). |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | No unrelated spans altered. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section is empty; all sections are populated. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol/monitoring labels match ER usage. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Labels preserved. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji indicators in the QRS. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Content condensed to one-page budget. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Metadata comment is first element after the doctype (lines 2–13). |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | ”—” delimiters at lines 3 and 12. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Values trimmed and unquoted. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | “er_filename: centrophenoxine_2026-0629-0402_Opus_ER.md” (line 4). |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | “qrs_prompt_version: 26.5.18” (line 5). |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” | 🟢 | “qrs_creation_date: 2026-0629-0402” (line 6). |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | “qrs_creator_ai_nickname: Opus” (line 7). |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. | 🟢 | “Opus”. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | “qrs_creator_ai_fullname: Opus 4.8” (line 8). |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier | 🟢 | “Opus 4.8”. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | “qrs_filename: centrophenoxine_2026-0629-0402_Opus_QRS.html” (line 9). |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All values clean. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet”. The [canonical_topic] is HTML-entity-encoded as needed. | 🟢 | “Centrophenoxine for Health & Longevity - Quick Reference Sheet” (line 21). |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed. | 🟢 | “Centrophenoxine for Health & Longevity” (line 416). |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | “06/29/2026” matches 2026-0629 (line 420). |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | “Opus 4.8” (line 424). |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header contains only title and the standard subline. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Distills the Conclusion (lines 398–402). |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 51 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | 1950s memory drug, age pigment, modest memory gains, thin/unconfirmed, short-term tolerability, long-term unknown, mislabeling all trace to the Conclusion. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | “Age pigment” in plain quotes; no acronyms. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial citations. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No statistics. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Sourced from line 264 (“Populations who should avoid it”). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | Pregnancy/breastfeeding, uncontrolled seizure disorders, unstable bipolar/severe anxiety, hypersensitivity. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Four <li> items. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash. Just the key fact. | 🟢 | Concise; no trailing clauses. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible. | 🟢 | “(epilepsy)” preserved on the seizure item. |
| 8.6 | When the ER uses ranking notation inside parens that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | 🟢 | No ranking notation present; not applicable in content but no symbol carried through. |
| 8.7 | If no [stop_items] are present the section is left empty | N/A | Contraindications are present. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Sourced from lines 254–264. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Six interactions listed; contraindications not duplicated. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Six <li> items. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash. Just the key fact. | 🟢 | Concise; no trailing clauses. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible. | 🟢 | Example drug lists preserved (donepezil/rivastigmine/galantamine; alpha-GPC/citicoline/DMAE/huperzine A; caffeine/methylphenidate/amphetamines; diphenhydramine/doxylamine). |
| 9.6 | When the ER uses ranking notation inside parens that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | 🟢 | No ranking notation carried through. |
| 9.7 | If no [caution_items] are present the section is left empty | N/A | Key interactions are present. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | Derived from Therapeutic Protocol and Risk Mitigation (lines 269–294). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose, Timing, Schedule. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three actionable aspects are present. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All three cells populated with ER-derived content. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | ER provides two distinct time-to-effect aspects (memory; acute effects); both captured, third hidden. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Memory effects (the graded benefit) listed first, acute effects second. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | 🟢 | Only two aspects exist; third set blank and hidden via display:none. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | Both used sets populated from Practical Considerations (line 335). |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Derived from Expected Benefits (lines 142–179). |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Concise label-only phrasing. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheticals carried over. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | High and Medium are empty and set to display:none; Low and Speculative populated. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | Derived from lines 195–236. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Concise label-only phrasing. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheticals carried over. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | High is empty and set to display:none; Medium/Low/Speculative populated. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from Monitoring Protocol (lines 355–381). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | BP & resting HR and CMP — the two measurable biomarkers in the ER table — are both listed. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Cadence text matches ER line 361. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from the qualitative markers (lines 372–381). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | Memory and recall, Mental clarity and focus, Energy and mood, Sleep, Headache or jaw tension — all five listed. |
Issues 29/06/2026 05:34
Pass rate 100.00%. No issues found.
Issues 29/06/2026 05:31
Pass rate 100.00%. No issues found.
Issues 29/06/2026 05:30
- 11.1 — Time-to-effect slot placement: The two available time-to-effect aspects occupy time_1 and time_3 (with time_2 hidden), leaving a gap; the two used sets should fill the first contiguous slots (time_1, time_2) with the trailing set hidden.
Fixes 29/06/2026 05:30
- 11.1 — Time-to-effect slot placement: Moved the “Acute effects / Hours to days” set from time_3 into time_2 (the contiguous second slot) and hid the now-unused time_3 set, so the two used time-to-effect aspects occupy the first contiguous slots.
Issues 29/06/2026 05:27
- 12.4 — Parenthetical not stripped in benefits: benefits_low retains
("age pigment")after “reduction of lipofuscin” (line 527); item 12.4 requires parenthetical content to be stripped, not preserved.
Fixes 29/06/2026 05:27
- 12.4 — Strip parenthetical in benefits: Removed the
("age pigment")gloss from the benefits_low item, leaving “reduction of lipofuscin” so no parenthetical content is preserved.
Issues 29/06/2026 05:22
- 11.1 — Third time-to-effect aspect not distinct: The ER provides only two distinct time-to-effect aspects — acute effects within hours-to-days and memory effects over weeks-to-months (Practical Considerations, line 335). The QRS fills a third set, time_2 “Meaningful trial / 8–12 weeks,” which is a trial-duration recommendation rather than a distinct time-to-effect aspect.
Fixes 29/06/2026 05:22
- 11.1 — Non-distinct time-to-effect set removed: Emptied the time_2 set (“Meaningful trial / 8–12 weeks”), a trial-duration recommendation rather than a distinct time-to-effect aspect, and hid its pcell via display:none, leaving the two genuine aspects (memory effects; acute effects).